Moreover, the scientific community has recently focused its attention on AT1R inhibitors and their possible benefit for patients infected by COVID-19 who experience pneumonia [49], but even in this regard, there are still some doubts about the AT1R antagonists’ effects. This evidence concerns the gene AGTR1 and susceptibility to pneumonia measurement.